Indutrade acquires Finnish medical technology company Labema

Labema is a technical trading company operating within the life science and biotechnology field, offering diagnostic equipment and supplies primarily to public healthcare, food industry and research laboratories. The company has a strong sales-oriented culture with high technical expertise in microbiology, molecular biology, food diagnostics and biobanking robotics, among others. Labema has 20 employees and is located in Helsinki, Finland.

“Labema has a strong entreprenurial spirit and expertise in developing deep, long lasting relationships with its customers and suppliers. It is also the first medical technology company we acquire in Finland and we are glad to welcome them to the Indutrade family”, said Bo Annvik, President and CEO of Indutrade.

The closing takes place today and Labema will be included in Indutrade's Business Area Finland. The acquisition is Indutrade's fifth in 2023 and is expected to have a marginally positive impact on Indutrade's earnings per share.  

Stockholm, 14 June 2023

INDUTRADE AB (publ)

For further information, please contact:
Bo Annvik, President and CEO
Phone +46 8 703 03 00

About Indutrade
Indutrade is an international technology and industrial business group that today consists of approximately 200 companies in some 30 countries, mainly in Europe. In a decentralised way, we aim to provide sustainable profitable growth by developing and acquiring successful companies managed by passionate entrepreneurs. Our companies develop, manufacture, and sell components, systems and services with significant technical content in selected niches. Our value-based culture, where people make the difference, has been the foundation of our success since the start in 1978. Indutrade's net sales totalled SEK 27 billion in 2022, and the share is listed on Nasdaq Stockholm in Sweden.